HC Wainwright Issues Positive Forecast for Microbot Medical (NASDAQ:MBOT) Stock Price

Microbot Medical (NASDAQ:MBOT) had its target price increased by equities research analysts at HC Wainwright from $7.00 to $9.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 371.20% from the stock’s previous close.

Microbot Medical Trading Down 4.0 %

MBOT stock opened at $1.91 on Friday. The company has a market capitalization of $38.66 million, a PE ratio of -2.39 and a beta of 1.46. Microbot Medical has a 12-month low of $0.82 and a 12-month high of $3.38. The business’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.07.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.